Cashu FinanceCashu Finance
  • Terminal
  • Spotlight
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. CELC

Market Cap: $3.22B

CI

Celcuity Inc.

CELC
NASDAQUSD
Purchase CELC
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

$65.54
+$0.29(0.44%)
At close: Oct 26, 15:44 EDT

Recently from Cashu

Celcuity Reports Improved Loss, Focuses on Growth in Innovative Cancer Treatment Strategies

Celcuity Prepares for Future Growth Amid Recent Earnings Release Celcuity, a biotechnology firm focused on advancing cancer treatment through its innovative drug discovery platform, has recently repor…

Cashu Finance·7 months ago

Celcuity's Precision Medicine Strategy: Advancing Targeted Cancer Therapies for Personalized Treatment

Navigating the Landscape of Precision Medicine: Celcuity’s Strategic Focus on Cancer Therapeutics Celcuity, a clinical-stage biotechnology company, is making significant strides in the realm of precis…

Cashu Finance·11 months ago

Celcuity's Resilient Strategy: Innovating Cancer Therapies Amid Market Volatility

Celcuity’s Strategic Positioning Amid Market Volatility Celcuity, a biotechnology company focused on developing innovative cancer therapies, navigates a challenging economic landscape marked by height…

Cashu Finance·11 months ago

Celcuity's Gedatolisib Moves Closer to FDA Approval for Advanced Breast Cancer Treatment

Celcuity's Gedatolisib Advances Towards FDA Approval, Offering New Hope in Breast Cancer Treatment Celcuity Inc., a biopharmaceutical company focused on innovative cancer therapies, celebrates a pivot…

Cashu Finance·11 months ago

Open

$107.89

Prev. Close

$65.25

High

$111.11

Low

$107.74

Company Profile

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

CEOBrian F. Sullivan
SectorHealthcare
IndustryBiotechnology
Employees155
IPO DateSep 19, 2017
ExchangeNASDAQ
Exchange NameNASDAQ
CurrencyUSD
Headquarters & Contact
Address2800 Campus Drive
City / State / ZIPMinneapolis, MN, 55441
CountryUnited States
Phone763 392 0767
Websitehttps://www.celcuity.com